Heart failure (HF) and kidney disease are two of the most important conditions affecting morbidity and mortality of adult subjects. Their prevalence is still growing because of aging of the general population and better treatment of acute conditions. Hypertension, diabetes, and atherosclerosis are coexisting risk factors both for HF and chronic kidney disease (CKD). In addition, there is evidence that HF or CKD may affect each other, leading to further progression of the disease.
An impairment of kidney function is present in 30-60% of the patients with HF and is an independent prognostic factor. Worsening of renal function (WRF) may also be related with poorer outcomes in these patients. Hemodynamic abnormalities such as venous congestion and a low cardiac output, neurohormonal and inflammatory activation, atherosclerosis, and diuretic treatment may all contribute to WRF in the patients with HF. Impaired kidney function is, on its turn, associated with abnormalities in the mineral metabolism, anemia, formation of advanced glycation end-products, further inflammatory and neurohormonal activation, reduced use of life saving therapies, such as inhibitors of the renin-angiotensin-aldosterone system (RAAS), which may all contribute to the increased rate and length of the hospitalizations and increased mortality of patients with HF.
Research has focused on the development of agents that improve kidney function and/or protect from its further impairment in patients with HF. However, so far no agent has been associated with long-term improvement in kidney function and outcomes in patients with HF. These results may be related to either the lack of a pathogenic role of kidney dysfunction in HF, insufficient efficacy of drugs tested and/or lack of accurate and sensitive markers of kidney function. Novel biomarkers, which may better measure changes in renal function, are promising and might contribute to a further understanding of the pathogenic role of kidney dysfunction in HF.
In this special issue of Heart Failure Reviews, experts in the field were invited to submit reviews on the definition, prevalence, prognostic role, and pathophysiological mechanisms of kidney dysfunction in heart failure, as well as the effects of treatment and the role of traditional and novel biomarkers. The first articles outline the definition, epidemiology, and clinical impact of CKD and WRF in the patients with HF. Ronco has summarized the main aspects of the definition and classification of the cardio-renal syndromes. He distinguished between the acute or chronic clinical setting with the primary mechanism in either the heart, the kidney, or both. Partially different pathophysiological mechanisms are involved in each of these subtypes [1] . The epidemiology, pathophysiology, and clinical characteristics of kidney dysfunction in acute or chronic HF, respectively, are thoroughly discussed in articles by Carubelli et al. and Dobre et al. [2, 3] .
The mechanisms leading to kidney dysfunction in the patients with HF have been thoroughly assessed in many recent studies. Neurohormonal activation with increased renal sympathetic stimulation and activation of the RAAS plays a major role causing renal vasoconstriction, and, probably more important, inflammation, oxidative stress, and fibrosis in the kidney. These are the basis for the longterm beneficial effects on kidney function, which have been associated with the administration of RAAS antagonists [4] . However, the beneficial effects of these agents may be counteracted by the secondary increase in prorenin and renin that may activate several alternative pathways, including the recently discovered pro-renin receptor. The role of these systems is thoroughly discussed by Schroten et al. [5] .
In addition to the RAAS, inflammatory activation, release of advanced glycation end-products, and atherosclerotic disease of the abdominal aorta have a major role [6] [7] [8] . Lastly, research has focused on the role of the hemodynamic abnormalities of HF. Low cardiac output and renal hypoperfusion are major determinants in patients with chronic HF. However, venous congestion and increased renal vein pressure and increased intra-abdominal pressure have a major role in patients with acutely decompensated HF. Reduced glomerular filtration pressure and interstitial edema with tubular damage in the kidney are among the main mechanisms leading to kidney dysfunction [9, 10] . Other mechanisms, such as abnormalities of vitamin D metabolism and anemia, play a major role [11, 12] .
The multitude of mechanisms and the pathogenesis of kidney dysfunction point out the inadequacy of its current assessment, simply based on serum creatinine measurements. Serum creatinine has a slow kinetic rising relatively late after acute kidney injury. It is also not sensitive to tubular damage, an event occurring early after kidney injury. It is dependent on dietary intake and muscle mass and, more important for the patients with HF, on volume status and renal perfusion. Thus, a large amount of recent research has been focused on new biomarkers of kidney function [13] . New biomarkers such as cystatin-C may better assess glomerular function and, particularly, may detect its impairment at an early stage and with a greater sensitivity, compared with serum creatinine [14] . Other markers are related with tubular damage and may allow for an earlier detection of acute kidney injury and a better prediction of events, mortality, rehospitalization, and/or WRF in patients with acute HF [13] .
Despite recent improvements in our knowledge about the disease, no major progress has been achieved in respect of prevention and treatment of kidney dysfunction in the patients with HF. The different agents and tools that have been proposed and the possible reasons for the recent results are also thoroughly discussed in this special issue [2, [15] [16] [17] . We have been fortunate to receive the contribution by leading experts in each of these topics. Organizing this issue has been fascinating and stimulating. It has been a nice and rewarding experience, and we are convinced this will be the case for our readers, too.
